Bank Of America Corp Genprex, Inc. Transaction History

Bank Of America Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.19 - $0.37 $3,919 - $7,633	-20,631 Reduced 99.05%	198 $0
Q2 2023 Aug 14, 2023	SELL	$0.74 - $1.1 $3,597 - $5,348	-4,862 Reduced 18.92%	20,829 $19,000
Q1 2023 May 12, 2023	BUY	$0.76 - $1.78 $15,640 - $36,630	20,579 Added 402.56%	25,691 $23,000
Q4 2022 Feb 10, 2023	SELL	$1.0 - $58.8 $12,986 - $763,576	-12,986 Reduced 71.75%	5,112 $7,000
Q3 2022 Nov 14, 2022	BUY	$1.32 - $58.0 $23,888 - $1.05 Million	18,097 Added 1809700.0%	18,098 $25,000
Q2 2022 Aug 12, 2022	SELL	$1.28 - $2.31 $1,395 - $2,517	-1,090 Reduced 99.91%	1 $0
Q1 2022 May 16, 2022	SELL	$1.82 - $3.5 $5,123 - $9,852	-2,815 Reduced 72.07%	1,091 $2,000
Q4 2021 Feb 08, 2022	SELL	$1.21 - $2.7 $15,109 - $33,714	-12,487 Reduced 76.17%	3,906 $5,000
Q3 2021 Nov 15, 2021	SELL	$2.59 - $3.36 $62,141 - $80,616	-23,993 Reduced 59.41%	16,393 $44,000
Q2 2021 Sep 13, 2021	BUY	$3.11 - $4.87 $125,600 - $196,679	40,386 New	40,386 $136,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $76.8M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.